Please complete as many details as possible and forward within one business day to:

Program Details

Form Completed By	Name of Program: TREATMENT OF HCV PATIENTS WITH DONATED "SOVALDI" MEDICINE IN THE REPUBLIC OF ARMENIA
Print Name: Naira Sargsyan	Name of Organisation: : "ARMENICUM" CJSC
Signature:	Date aware of Safety Information:
Telephone Number:	Country of Occurrence of Safety Information: ARMENIA
Fax No/Email: sknarina70@mail.ru	

Patient Details

DOB: 1964 (or year of birth):	**Sex:** Male☑ Female ☐	**Initials:** G.H.	**Age:** 52

Drug Details (Provide additional drugs on a separate page)

Lot/Batch No	Reason For Taking	Stop Date (or On-going) (DD/MON/YYYY)	Start Date (DD/MON/YYYY)	Route	Dose	Drug Name
TZDPD	HEP C	On-going	14/06/2017	PO	400MG	SOVALDI
		On-going	14/06/2017	PO	60MG	DACLATASVIR
		On-going	14/06/2017	PO	1000MG	RIBAVIRIN

Safety Information Details:

Please provide a short summary of the adverse event(s) (AE) or other safety information (e.g. reports such as pregnancy, death, hospitalization, overdose, misuse, abuse, medication error, lack of effect, off-label use, occupational exposure, AEs associated with product complaints or AEs in an infant following exposure from breastfeeding). Please include the start and stop dates and the outcome of the event(s) or confirm if the event(s) is/are still ongoing. Please also provide any treatment given to treat the event(s), any relevant medical history and for reports of death include the date of death – continue on another page if necessary.

During the 2-3rd month of the treatment with sovaldi, daclatasvir and ribavirin patient experienced weakness, insomnia, dizziness, appetite decreased, nausea, anemia, itching emotional lability (anxiety-depressive syndrome).

On 04.08.2017 aggravation of urolithiasis occurred.

Patient was hospitalized from 09.08.2017 to 17.08.2017

On 18.08.2017 ribavirin dose was dincreased to 800mg, on 20.08.2017 - to 400mg.

To treat anemia patient was administrated Folic Acid.

Has this safety information previously been reported to a Regulatory Authority? Yes ☐ No ☑	Does the Reporter consider that the event(s) were possibly related to the drug? Yes ☑ No ☐

Reporter Details (i.e. who notified you of the above safety information?)

Is the Reporter a: Doctor ☑ Nurse ☐ Pharmacist ☐ Non-healthcare professional (e.g. patient, relative)* ☐

If the Reporter is a Healthcare Professional (HCP) and they are willing to provide us with their contact information, please record below

**If the Reporter is a Non-healthcare professional, please confirm if they are willing to provide contact information for their HCP:*

Yes ☐ (Please record HCP details below) No ☐

HCP Address First Line: Town/City: County/State: Postcode/Zip code:	HCP Name: HCP Telephone No/FAX No: HCP Email:

used to comply with applicable laws and regulations. By providing us with information you are consenting to the control and processing of this personal or sensitive data by MoLHSA in accordance with applicable data protection laws and the MoLHSA privacy policy.